# Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2

> **NCT05069649** · PHASE3 · COMPLETED · sponsor: **Materia Medica Holding** · enrollment: 1057 (actual)

## Conditions studied

- Immunization Against COVID-19

## Interventions

- **DRUG:** Ergoferon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05069649
- **Lead sponsor:** Materia Medica Holding
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2022-04-14
- **Final completion:** 2022-04-14
- **Target enrollment:** 1057 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05069649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05069649, "Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05069649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*